Abstract Library

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients

Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Wakelin K,

Keywords: diagnosis, ongoing care, primary healthcare, NETs, quality of life, symptom management, NET symptoms,

#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs

Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lim S, Reynolds M, Rees D, Chaudhry R, Blackhouse J,

Keywords: Nutrition, Dietetics, Malnutrition, Vitamin Deficiency, Screening,

#2130 Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service

Introduction: Patients with NETs have worse health-related quality of life (HRQoL) than the general population. Technological advances have significantly increased electronic patient-reported outcome (ePRO) data collection capabilities. There is little longitudinal PRO/ePRO data and limited data on gastrointestinal symptoms, particularly ‘diarrhoea’, in NET patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Reynolds M

Authors: Reynolds M, Tucker L, Ankita B, Powell C, Hopps R,

Keywords: Quality of Life, Symptoms, ePRO, Diarrhoea, NET service, Longitudinal Data, CABARET, app,

#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses

Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Whyand T, Davies P, Bouvier C,

Keywords: B12, SSA, Side effects, Fat soluble vitamins,